PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisFrancesco Passiglia, Antonio Russo, Sérgio Rizzo et al.|Oncotarget|2016Cited by 166
Entrectinib: a potent new TRK, ROS1, and ALK inhibitorChristian Rolfo, Luis E. Raez, Rossana Ruiz et al.|Expert Opinion on Investigational Drugs|2015Cited by 153